Development of novel therapeutic methods for innovative bladder cancer by drug repositioning

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10613
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Hyogo Medical University
• Principal Investigator: GOTOH AKINOBU 兵庫医科大学, 医学部, 教授 (70283885)
• Co-Investigator(Kenkyū-buntansha): 長屋 寿雄 兵庫医科大学, 医学部, 助教 (60464343)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 膀胱癌 / ナフトピジル / ドラッグ・リポジショニング / QOL

Outline of Final Research Achievements

Bladder cancer has a high recurrence rate and low survival rate, and patient's quality of life are significantly reduced due to side effects of treatment and surgical treatment. In response, we aimed to develop novel therapeutic and preventive methods focusing on QOL using naftopidil, an α1 blocker-type oral dysuria treatment, by taking advantage of the idea of drug repositioning (DR). We were able to prepare a formulation that can expect antitumor effect from two directions by naftopidil in blood and its urinary metabolite. It is a promising achievement of establishing a novel therapeutic method for bladder cancer with safety- established naftopidil, its application for prevention of recurrence, and development of novel anticancer drugs.

Free Research Field

細胞・遺伝子治療、泌尿器系腫瘍